You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Boehringer Ingelheim
Moodys
Merck
Harvard Business School

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NEXTERONE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for NEXTERONE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01401647 Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia Active, not recruiting American Heart Association Phase 3 2012-05-01 The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo.
NCT01401647 Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia Active, not recruiting Canadian Institutes of Health Research (CIHR) Phase 3 2012-05-01 The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo.
NCT01401647 Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia Active, not recruiting Defence Research and Development Canada Phase 3 2012-05-01 The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo.
NCT01401647 Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia Active, not recruiting Heart and Stroke Foundation of Canada Phase 3 2012-05-01 The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo.
NCT01401647 Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia Active, not recruiting National Heart, Lung, and Blood Institute (NHLBI) Phase 3 2012-05-01 The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo.
NCT01401647 Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia Active, not recruiting U.S. Army Medical Research and Materiel Command Phase 3 2012-05-01 The primary objective of the trial is to determine if survival to hospital discharge is improved with early therapeutic administration of a new Captisol-Enabled formulation of IV amiodarone (Nexterone-PM101) compared to placebo.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for NEXTERONE

Condition Name

Condition Name for NEXTERONE
Intervention Trials
Hepatitis C 1
Cardiac Arrest 1
Atrial Fibrillation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for NEXTERONE
Intervention Trials
Ventricular Fibrillation 1
Tachycardia, Ventricular 1
Tachycardia 1
Out-of-Hospital Cardiac Arrest 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for NEXTERONE

Trials by Country

Trials by Country for NEXTERONE
Location Trials
United States 8
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for NEXTERONE
Location Trials
New York 1
Wisconsin 1
Washington 1
Texas 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for NEXTERONE

Clinical Trial Phase

Clinical Trial Phase for NEXTERONE
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for NEXTERONE
Clinical Trial Phase Trials
Active, not recruiting 2
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for NEXTERONE

Sponsor Name

Sponsor Name for NEXTERONE
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 1
Heart and Stroke Foundation of Canada 1
University of Calgary 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for NEXTERONE
Sponsor Trials
Other 6
NIH 2
Industry 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Mallinckrodt
Colorcon
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.